Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17222422rdf:typepubmed:Citationlld:pubmed
pubmed-article:17222422lifeskim:mentionsumls-concept:C0025663lld:lifeskim
pubmed-article:17222422lifeskim:mentionsumls-concept:C0021756lld:lifeskim
pubmed-article:17222422lifeskim:mentionsumls-concept:C0009393lld:lifeskim
pubmed-article:17222422lifeskim:mentionsumls-concept:C1511790lld:lifeskim
pubmed-article:17222422lifeskim:mentionsumls-concept:C0301872lld:lifeskim
pubmed-article:17222422lifeskim:mentionsumls-concept:C0920508lld:lifeskim
pubmed-article:17222422lifeskim:mentionsumls-concept:C1554184lld:lifeskim
pubmed-article:17222422lifeskim:mentionsumls-concept:C0521115lld:lifeskim
pubmed-article:17222422pubmed:issue1-2lld:pubmed
pubmed-article:17222422pubmed:dateCreated2007-3-12lld:pubmed
pubmed-article:17222422pubmed:abstractTextThe single color IFN-gamma ELISPOT assay has become a standard for assessing HIV-specific immune responses in HIV-infected subjects. However, recent data suggests that single cytokine detection for immune monitoring of HIV-infected individuals may not be sufficient to fully describe virus-specific immune responses. Here, we have designed and validated a dual color ELISPOT assay capable of detecting both IL-2 and IFN-gamma secreting cells simultaneously in response to HIV antigens. We found that a cell input number of 200,000 cells/well provided a good balance between limited availability of cells due to blood volume restrictions and ability to detect all cytokine secretion patterns. The simultaneous detection of IL-2 and IFN-gamma resulted in a decreased magnitude of IFN-gamma but not IL-2 responses. Measures of intra- and inter-assay variability for the dual color ELISPOT assay were comparable to that seen for single cytokine ELISPOT assay with coefficients of variation below 20% for IL-2, IFN-gamma and dual secretion. Although CD8+ T cells mediated most HIV-specific responses in infected subjects, CD4+ T cells mediated responses to HIV were also detected. Features of this assay such as high throughput, cell number requirement and cytokine choice should make this assay a valuable tool for screening for HIV-specific immune responses in several clinically relevant settings.lld:pubmed
pubmed-article:17222422pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17222422pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17222422pubmed:languageenglld:pubmed
pubmed-article:17222422pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17222422pubmed:citationSubsetIMlld:pubmed
pubmed-article:17222422pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17222422pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17222422pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17222422pubmed:statusMEDLINElld:pubmed
pubmed-article:17222422pubmed:monthMarlld:pubmed
pubmed-article:17222422pubmed:issn0022-1759lld:pubmed
pubmed-article:17222422pubmed:authorpubmed-author:RoutyJean-Pie...lld:pubmed
pubmed-article:17222422pubmed:authorpubmed-author:BernardNicole...lld:pubmed
pubmed-article:17222422pubmed:authorpubmed-author:PeretzYoavYlld:pubmed
pubmed-article:17222422pubmed:authorpubmed-author:SekalyRafick-...lld:pubmed
pubmed-article:17222422pubmed:authorpubmed-author:BoulasselMoha...lld:pubmed
pubmed-article:17222422pubmed:authorpubmed-author:TremblayCecil...lld:pubmed
pubmed-article:17222422pubmed:authorpubmed-author:BoisvertMarie...lld:pubmed
pubmed-article:17222422pubmed:authorpubmed-author:BouletSalixSlld:pubmed
pubmed-article:17222422pubmed:authorpubmed-author:NdongalaMiche...lld:pubmed
pubmed-article:17222422pubmed:issnTypePrintlld:pubmed
pubmed-article:17222422pubmed:day30lld:pubmed
pubmed-article:17222422pubmed:volume320lld:pubmed
pubmed-article:17222422pubmed:ownerNLMlld:pubmed
pubmed-article:17222422pubmed:authorsCompleteYlld:pubmed
pubmed-article:17222422pubmed:pagination18-29lld:pubmed
pubmed-article:17222422pubmed:dateRevised2011-10-17lld:pubmed
pubmed-article:17222422pubmed:meshHeadingpubmed-meshheading:17222422...lld:pubmed
pubmed-article:17222422pubmed:meshHeadingpubmed-meshheading:17222422...lld:pubmed
pubmed-article:17222422pubmed:meshHeadingpubmed-meshheading:17222422...lld:pubmed
pubmed-article:17222422pubmed:meshHeadingpubmed-meshheading:17222422...lld:pubmed
pubmed-article:17222422pubmed:meshHeadingpubmed-meshheading:17222422...lld:pubmed
pubmed-article:17222422pubmed:meshHeadingpubmed-meshheading:17222422...lld:pubmed
pubmed-article:17222422pubmed:meshHeadingpubmed-meshheading:17222422...lld:pubmed
pubmed-article:17222422pubmed:meshHeadingpubmed-meshheading:17222422...lld:pubmed
pubmed-article:17222422pubmed:year2007lld:pubmed
pubmed-article:17222422pubmed:articleTitleA dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses.lld:pubmed
pubmed-article:17222422pubmed:affiliationResearch Institute of the McGill University Health Center, Montreal, Canada.lld:pubmed
pubmed-article:17222422pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17222422pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17222422pubmed:publicationTypeEvaluation Studieslld:pubmed
pubmed-article:17222422pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17222422lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17222422lld:pubmed